Home » NICE Grants Prelim Approval to Novartis, Astellas Drugs, but Not Janssen Drug
NICE Grants Prelim Approval to Novartis, Astellas Drugs, but Not Janssen Drug
The UK’s health cost-benefit watchdog has given provisional approval in draft guidances for Novartis’ novel heart failure drug Entresto, and recommended Astellas’ enzalutamide as a treatment for prostate cancer.
Meanwhile, NICE withheld recommending Janssen’s prostate cancer drug Zytiga (abiraterone acetate), saying the drug is a well-tolerated treatment that delays chemotherapy, but that it was not convinced the “uncertain evidence” for the long-term treatment benefit justified the cost, which was “significantly above what it would normally consider acceptable.”
Upcoming Events
-
14May
-
23May
-
30May
-
20Jun
-
21Oct